News | December 16, 2007

FDA Clears Medtronic’s New Insertable Cardiac Monitors

December 17, 2007 - Medtronic Inc. today announced it received FDA clearance of the Reveal DX and Reveal XT, new insertable cardiac monitors (ICMs) designed to provide diagnostic and monitoring insights to cardiologists managing their patients with syncope (fainting) or abnormal heart rhythms, including ventricular tachyarrhythmias (VT), fast ventricular tachyarrhythmias (FVT), bradyarrhythmias and asystole.

The Reveal DX continuously monitors the heart’s electrical activity in order to help physicians diagnose whether or not symptoms such as fainting, dizziness and unexplained seizure-like episodes have a cardiovascular cause. Causes of syncope can be heart rhythm disturbances or abnormalities in the structure of the heart. Syncope can lead to serious injury or can be a precursor to sudden cardiac death. Approximately 1.5 million people worldwide suffer from unexplained syncope. In almost 10 percent of patients, syncope has a cardiac cause; in 50 percent, a non-cardiac cause; and in 40 percent of patients the cause of syncope is unknown, according to a study published in the New England Journal of Medicine (E.S. Soteriades et al. N Eng J Med. 2002; 347 (12):878-885.). It is a leading cause of emergency room visits. Syncope is difficult to diagnose as syncopal episodes are often too infrequent and unpredictable for detection with conventional monitoring techniques.

Placed just under the skin of the chest area using local anesthesia during an outpatient procedure, the Reveal DX monitor records important cardiac rhythm data, which may help a physician to diagnose the patient so the appropriate treatment can be undertaken. The device weighs 15 grams and is approximately the size of a memory stick. Unlike a pacemaker or implantable cardioverter-defibrillator, there are no leads that extend from the device into the heart’s chambers. To store an electrocardiogram (ECG) at the time of an episode, a patient places a hand-held, pager-sized activator over the device and presses a button. Later a physician analyzes the stored information and determines if the episode was caused by an abnormal heart rhythm.

The Reveal DX will be commercially available in the U.S. beginning next week and the Reveal XT will follow.

For more information: www.medtronic.com

Related Content

Researchers File Patent for Tiny Blood Flow Sensor

Image courtesy of Flinders University

News | Implantable Cardiac Monitor (ICM) | July 09, 2019
South Australian researchers are developing a tiny fiber-optic sensor, which has the potential to change the way blood...
Biotronik Launches Biomonitor III Injectable Cardiac Monitor in the CE Region
News | Implantable Cardiac Monitor (ICM) | July 01, 2019
Biotronik announced the market release of its new injectable cardiac monitor (ICM), Biomonitor III, following approval...
Abbott Launches Next-generation Confirm RX Implantable Cardiac Monitor
News | Implantable Cardiac Monitor (ICM) | May 06, 2019
Abbott announced the launch of a new, smarter heart monitor for better arrhythmia detection — positive news for people...
The Angel Medical Systems' AngelMed Guardian System is an implantable cardiac monitor intended to detect and alert patients of a potential heart attack.

 The Angel Medical Systems' AngelMed Guardian System is an implantable cardiac monitor intended to detect and alert patients of a potential heart attack. 

Technology | Implantable Cardiac Monitor (ICM) | May 09, 2018
 May 9, 2018 — The U.S.
Abbott SJM St. Jude Confirm RX implantable cardiac monitor (ICM).

The Abbott Confirm RX implantable cardiac monitor (ICM) is smaller than a computer thumb-drive and in implanted in a simple in-office procedure just under the skin.

Technology | Implantable Cardiac Monitor (ICM) | October 23, 2017
October 23, 2017 – The U.S.
Digital Health Company Murj Announces $4.5 Million in Financing
News | Implantable Cardiac Monitor (ICM) | April 19, 2017
Murj Inc., a digital health company that helps manage implantable cardiac device data, announced more than $4.5 million...
Medtronic, Reveal LINQ ICM, insertable cardiac monitor, FDA clearance, TruRhythm Detection
Technology | Implantable Cardiac Monitor (ICM) | March 15, 2017
Medtronic plc announced U.S. Food and Drug Administration (FDA) 510(k) clearance for its Reveal LINQ Insertable Cardiac...
heart monitoring technology, climbers, high altitudes, Circulation study, cardiac diagnostics, Medtronic, Reveal LINQ
News | Implantable Cardiac Monitor (ICM) | March 14, 2017
Climbing above 4,000 meters can provoke abnormal heart rhythms in otherwise healthy mountaineers, with the...
Biotronik, ProMRI Configurator tool, MR-conditional cardiac devices, ProMRI SystemCheck
Technology | Implantable Cardiac Monitor (ICM) | February 14, 2017
Biotronik has developed an online tool that streamlines the workflow for physicians selecting the right magnetic...
Biotronik, BioMonitor 2 implantable cardiac monitor, BioInsight clinical study, first patients enrolled
News | Implantable Cardiac Monitor (ICM) | January 20, 2017
Biotronik has enrolled the first patients in the BioInsight clinical study evaluating the safety and feasibility of...
Overlay Init